Predicted to be involved in several processes, including negative regulation of branching involved in ureteric bud morphogenesis; negative regulation of cellular component organization; and negative regulation of substrate adhesion-dependent cell spreading. Predicted to act upstream of or within regulation of epithelial cell proliferation and ureteric bud morphogenesis. Predicted to be located in basal plasma membrane and lateral plasma membrane. Predicted to be active in extracellular space and nucleus. Human ortholog(s) of this gene implicated in corneal dystrophy and gelatinous drop-like corneal dystrophy. Orthologous to human TACSTD2 (tumor associated calcium signal transducer 2); INTERACTS WITH 17alpha-ethynylestradiol; 17beta-estradiol 3-benzoate; 6-propyl-2-thiouracil.
[Estradiol co-treated with Progesterone] results in decreased expression of TACSTD2 mRNA, [Estradiol co-treated with TGFB1 protein] results in decreased expression of TACSTD2 mRNA
[bis(4-hydroxyphenyl)sulfone co-treated with Tretinoin] results in decreased expression of TACSTD2 mRNA, [bisphenol F co-treated with Tretinoin] results in decreased expression of TACSTD2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA
[[Gasoline co-treated with 1-Butanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TACSTD2 mRNA
[[Gasoline co-treated with Ethanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TACSTD2 mRNA
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in increased expression of TACSTD2 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA
[Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of TACSTD2 mRNA, [Air Pollutants results in increased abundance of Ozone] which results in increased expression of TACSTD2 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA